505 related articles for article (PubMed ID: 11033070)
1. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.
Krishna R; Mayer LD
Eur J Pharm Sci; 2000 Oct; 11(4):265-83. PubMed ID: 11033070
[TBL] [Abstract][Full Text] [Related]
2. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
4. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
6. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
[TBL] [Abstract][Full Text] [Related]
7. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators.
Krishna R; Mayer LD
Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):163-74. PubMed ID: 12678765
[TBL] [Abstract][Full Text] [Related]
8. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
Choudhuri SK; Chatterjee A
Anticancer Drugs; 1998 Oct; 9(9):825-32. PubMed ID: 9840730
[TBL] [Abstract][Full Text] [Related]
9. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
11. Characterization and modulation of transitional cell carcinoma cell lines with acquired multidrug resistance.
Yu DS; Chang SY; Ma CP
Br J Urol; 1998 Feb; 81(2):234-40. PubMed ID: 9488065
[TBL] [Abstract][Full Text] [Related]
12. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
Bansal T; Jaggi M; Khar RK; Talegaonkar S
J Pharm Pharm Sci; 2009; 12(1):46-78. PubMed ID: 19470292
[TBL] [Abstract][Full Text] [Related]
13. Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators.
Orlowski S; Mir LM; Belehradek J; Garrigos M
Biochem J; 1996 Jul; 317 ( Pt 2)(Pt 2):515-22. PubMed ID: 8713080
[TBL] [Abstract][Full Text] [Related]
14. [Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma].
Okano M; Kawamoto S; Nezasa S; Tamaki M; Ehara H; Yamada S; Deguchi T; Kawada Y
Nihon Hinyokika Gakkai Zasshi; 1996 Aug; 87(8):1041-7. PubMed ID: 8831211
[TBL] [Abstract][Full Text] [Related]
15. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance.
Johnson WW
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):501-14. PubMed ID: 12500430
[TBL] [Abstract][Full Text] [Related]
17. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
19. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]